251. Utilizing targeted gene therapy with nanoparticles binding alpha v beta 3 for imaging and treating choroidal neovascularization
- Author
-
Demetrios G. Vavvas, Miin Roh, Evangelos S. Gragoudas, Shintaro Nakao, Hani Salehi-Had, Joan W. Miller, Samira Guccione, Toshio Hisatomi, Andrea Giani, and Ivana K. Kim
- Subjects
Male ,Pathology ,medicine.medical_specialty ,Alpha-v beta-3 ,genetic structures ,Genetic enhancement ,Science ,Green Fluorescent Proteins ,Apoptosis ,Gene delivery ,Light Coagulation ,chemistry.chemical_compound ,In vivo ,medicine ,Animals ,Biology ,Genes, Dominant ,Multidisciplinary ,medicine.diagnostic_test ,Chemistry ,Rhodamines ,Lasers ,Macrophages ,Endothelial Cells ,Genetic Therapy ,Fluorescein angiography ,Integrin alphaVbeta3 ,Choroidal Neovascularization ,eye diseases ,Rats ,Ophthalmology ,Choroidal neovascularization ,Macular Disorders ,Bionanotechnology ,Mutation ,Systemic administration ,Retinal Disorders ,Medicine ,sense organs ,medicine.symptom ,Preclinical imaging ,Research Article ,Biotechnology ,Plasmids - Abstract
PurposeThe integrin αvβ3 is differentially expressed on neovascular endothelial cells. We investigated whether a novel intravenously injectable αvβ3 integrin-ligand coupled nanoparticle (NP) can target choroidal neovascular membranes (CNV) for imaging and targeted gene therapy.MethodsCNV lesions were induced in rats using laser photocoagulation. The utility of NP for in vivo imaging and gene delivery was evaluated by coupling the NP with a green fluorescing protein plasmid (NP-GFPg). Rhodamine labeling (Rd-NP) was used to localize NP in choroidal flatmounts. Rd-NP-GFPg particles were injected intravenously on weeks 1, 2, or 3. In the treatment arm, rats received NP containing a dominant negative Raf mutant gene (NP-ATPμ-Raf) on days 1, 3, and 5. The change in CNV size and leakage, and TUNEL positive cells were quantified.ResultsGFP plasmid expression was seen in vivo up to 3 days after injection of Rd-NP-GFPg. Choroidal flatmounts confirmed the localization of the NP and the expression of GFP plasmid in the CNV. Treating the CNV with NP-ATPμ-Raf decreased the CNV size by 42% (PConclusionSystemic administration of αvβ3 targeted NP can be used to label the abnormal blood vessels of CNV for imaging. Targeted gene delivery with NP-ATPμ-Raf leads to a reduction in size and leakage of the CNV by induction of apoptosis in the CNV.
- Published
- 2011